Doctors use a familial Alzheimer's genetic panel to decide whether a patient over 65 qualifies for an amyloid-lowering drug and how closely that patient must be watched while taking it. The panel most often orders is ApoE ε4 genotyping, and the result changes the treatment plan before a prescription is written. That shift happened because the drugs themselves demand it. The FDA's label for lecanemab (Leqembi) requires ApoE ε4 testing before treatment starts, tying a genetic result directly to a prescribing decision for the first time in routine Alzheimer's care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why ApoE Testing Became a Prerequisite for Treatment
- What a Positive or Negative ApoE Result Actually Means
- Why Most Patients Over 65 Don't Get APP/PSEN1/PSEN2 Sequencing
- When Predictive Testing of a Symptom-Free Relative Makes Sense
- The Counseling Gap Patients Should Ask About
- Frequently Asked Questions
Why ApoE Testing Became a Prerequisite for Treatment
Lecanemab carries a boxed warning for amyloid-related imaging abnormalities, or ARIA — swelling or bleeding in the brain that shows up on MRI scans. The FDA label requires ApoE ε4 genotyping before treatment because that risk is not evenly distributed; it depends on how many copies of the ε4 variant a patient carries. Patients who inherit two copies of ApoE ε4, called homozygotes, make up about 15% of Alzheimer's patients.
The Leqembi label states this group faces higher rates of ARIA, including serious and severe radiographic cases, compared with people who carry one copy or none. That difference is large enough to change how a doctor counsels a patient and how often they order follow-up imaging. A patient does not have to agree to testing to receive the drug. The FDA label directs doctors to discuss ARIA risk by genotype before testing, and states that a patient who declines can still be treated — but the doctor then has no way to know whether that patient is a homozygote facing the highest risk tier.
What a Positive or Negative ApoE Result Actually Means
An ApoE ε4 result is not a diagnosis. Reviews on the subject stress that ε4 is a risk-modifying gene — neither necessary nor sufficient to cause Alzheimer's — so a positive result in a cognitively healthy older adult signals elevated risk and altered drug eligibility, not confirmation of disease, according to a 2022 review discussed in Neurology: Clinical Practice. This distinction matters because it reframes what the test is for.
Doctors are not using it to answer "does this patient have Alzheimer's" — a cognitive workup and biomarker testing answer that question separately. They are using ApoE genotyping to answer a narrower question: how aggressively can this specific patient be treated with an amyloid-lowering drug, and how closely do they need to be monitored. For decades, routine clinical ApoE testing was discouraged. The 2011 joint practice guidelines from the National Society of Genetic Counselors and the American College of Medical Genetics recommended against it, and that guidance is now being revisited by a dedicated NSGC Dementia Workgroup specifically because the new anti-amyloid drugs gave the test a clinical use it previously lacked.
Why Most Patients Over 65 Don't Get APP/PSEN1/PSEN2 Sequencing
ApoE genotyping is separate from testing the genes that cause early-onset familial Alzheimer's: APP, PSEN1, and PSEN2. These are rare, single-gene mutations that run in families and typically cause symptoms decades earlier than 65. A payer policy summarizing GeneReviews-style data shows why this sequencing is reserved for younger patients with a strong family history.
PSEN1 sequencing detects roughly 98% of mutations attributed to that gene, PSEN2 under 5%, and APP testing covers only 10–15% of cases — but that's testing for mutations that mostly only exist in early-onset cases to begin with. The numbers explain why this panel rarely applies to patients diagnosed after 65. The same policy notes early-onset Alzheimer's accounts for only 2–10% of all cases, and a causative mutation turns up in just 30–50% of those early-onset cases. Most patients, including nearly all patients over 65, have no identifiable single-gene cause, so sequencing APP, PSEN1, and PSEN2 would not explain their disease.
When Predictive Testing of a Symptom-Free Relative Makes Sense
Doctors do order APP/PSEN1/PSEN2 testing on asymptomatic adults in one specific circumstance: when a family already has a known mutation and a relative wants to know their own status before any symptoms appear. This is treated differently from standard diagnostic testing because of what a positive result means. The inheritance pattern is autosomal dominant with high penetrance, so a positive result is essentially predictive of future disease, not just a risk factor.
Clinical guidance advises that this kind of predictive testing happen only alongside formal genetic counseling, given the weight of what the result tells someone about their own future. This counseling requirement doesn't disappear once a patient turns 65 — it applies whenever someone from a known-mutation family seeks a predictive answer, regardless of age. It's a different conversation from ApoE testing tied to a drug decision, and doctors keep the two processes distinct.
The Counseling Gap Patients Should Ask About
Genetic counseling before ApoE testing is recommended, but it isn't always built into the process the way it is for predictive APP/PSEN1/PSEN2 testing. A 2026 UK survey published in BJPsych Open found most respondents wanted face-to-face genetic counseling before ApoE-ε4 testing and called for formal counseling guidelines to catch up with how the test is now being used.
A patient weighing lecanemab or a similar drug can ask their doctor directly what the ApoE result will be used for, whether genetic counseling is available before the blood draw, and what the result will mean for monitoring if they turn out to be a homozygote. These are reasonable questions given how new this use of the test is — the drug's own label ties eligibility to a genotype that clinical counseling practices have not fully caught up to addressing.
Frequently Asked Questions
Does an ApoE ε4 positive result mean a patient has Alzheimer's?
No. Reviews describe ApoE ε4 as a risk-modifying gene that is neither necessary nor sufficient to cause Alzheimer's, so a positive result signals elevated risk and changes drug eligibility rather than confirming disease, according to a review discussed in Neurology: Clinical Practice.
Can a patient still get lecanemab if they refuse ApoE testing?
Yes. The FDA label allows treatment without testing, but the doctor then cannot determine whether the patient is a homozygote facing the highest ARIA risk.
Why don't most people over 65 get tested for APP, PSEN1, or PSEN2 mutations?
Those mutations cause early-onset familial Alzheimer's, which accounts for only 2–10% of all cases, and a cause is identified in just 30–50% of those early-onset cases, according to a payer policy summarizing GeneReviews-style data. Most patients diagnosed after 65 have no single-gene cause to find.
